{"id":"W2032810181","doi":"10.1016/j.bbmt.2009.11.021","title":"Allogeneic Hematopoietic Cell Transplant for Prolymphocytic Leukemia","year":2009,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; Office of Naval Research; Health Resources and Services Administration; Association of Medical Microbiology and Infectious Disease Canada; Society for Healthcare Epidemiology of America; Hospira; Infectious Diseases Society of America; CellGenix; Medical College of Wisconsin; Blue Cross and Blue Shield Association; American Society for Blood and Marrow Transplantation; Kiadis Pharma; Therakos; Centers for Disease Control and Prevention; Celgene; Osiris Therapeutics; WellPoint; Teva Pharmaceutical Industries; Oncology Nursing Society; Aetna; National Marrow Donor Program; AABB; U.S. Department of Health and Human Services; Astellas Pharma US; Amgen; U.S. Department of Defense; National Heart, Lung, and Blood Institute; Sysmex Corporation","keywords":"Medicine; Prolymphocytic leukemia; Internal medicine; Cumulative incidence; Confidence interval; Oncology; Population; Incidence (geometry); Hematopoietic cell; Leukemia; Transplantation; Surgery; Haematopoiesis; Stem cell; Chronic lymphocytic leukemia","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001919329,0.0001590836,0.0003522489,0.0001169677,0.00005518875,0.000005040357,0.0000741975,0.0001987632,0.00001369808],"category_scores_gemma":[0.000009691161,0.000132586,0.00009857323,0.000086178,0.0001315999,0.00003924049,0.00000290634,0.00007691819,0.000002269513],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002645578,"about_ca_system_score_gemma":0.001330638,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004833174,"about_ca_topic_score_gemma":0.000009624801,"domain_scores_codex":[0.9989261,0.00003590542,0.0003236089,0.0002998297,0.000113688,0.0003008878],"domain_scores_gemma":[0.9994678,0.0001333843,0.00007232435,0.0001504026,0.00006169971,0.0001143222],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.001794537,0.0001696527,0.001120639,0.001783401,0.00009315295,0.00005604944,0.0008647038,0.000007750687,0.9896353,0.001053983,0.00003474689,0.00338604],"study_design_scores_gemma":[0.03880105,0.002991902,0.002064146,0.0002701923,0.001284916,0.001698369,0.00005950844,0.0006359495,0.9503543,0.001389137,0.0002003027,0.0002501953],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9941617,0.00221435,0.001867261,0.0002289454,0.00004810415,0.0007879204,0.00007256068,0.00003898267,0.0005801687],"genre_scores_gemma":[0.9954942,0.002317416,0.001497929,0.0001889425,0.00005585112,0.00004013312,0.0002635754,0.00001301368,0.0001289432],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03928101,"threshold_uncertainty_score":0.5406699,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0131323330492819,"score_gpt":0.2717403369524214,"score_spread":0.2586080039031395,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}